Multiple sclerosis trials recruiting in District of Columbia

All Multiple sclerosis trials nationally

Cities in District of Columbia

Recruiting trials in District of Columbia

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
  NCT06665165 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
  NCT07224373 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
  NCT06441617 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
  NCT05285891 · Phase: Phase 4 · Ages: 18 Years to 55 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · District of Columbia: Washington D.C.
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.